普拉克索联合盐酸苯海索治疗帕金森病患者的效果

Effects of Pramipexole combined with Benzhexol hydrochloride in treatment of patients with Parkinson’s disease

目的:观察普拉克索联合盐酸苯海索治疗帕金森病患者的效果。方法:选取2019年8月至2021年8月该院收治的94例帕金森病患者进行前瞻性研究,按随机数字表法将其分为对照组和观察组各47例。对照组采用盐酸苯海索治疗,观察组在对照组基础上联合普拉克索治疗,比较两组临床疗效、治疗前后帕金森综合评分量表(UPDRS)评分、认知功能[简易精神状态检查量表(MMSE)]评分、生命质量[39项帕金森病生活质量问卷(PDQ-39)]评分、血清学指标[胱抑素C(CysC)、脑源性神经营养因子(BDNF)、白细胞介素-1β(IL-1β)]水平和治疗期间不良反应发生率。结果:观察组治疗总有效率为93.62%(44/47),高于对照组的78.72%(37/47),差异有统计学意义(P<0.05);治疗后,两组Ⅰ、Ⅱ、Ⅲ部分UPDRS评分均低于治疗前,且观察组低于对照组,差异有统计学差异(P<0.05);治疗后,观察组MMSE评分高于对照组,PDQ-39评分低于对照组,差异均有统计学意义(P<0.05);治疗后,两组CysC、IL-1β水平均低于治疗前,且观察组低于对照组,两组BDNF水平均高于治疗前,且观察组高于对照组,差异有统计学意义(P<0.05);两组不良反应发生率比较,差异无统计学意义(P>0.05)。结论:普拉克索联合盐酸苯海索治疗帕金森病患者可提高治疗总有效率和认知功能评分,改善血清学指标水平,降低帕金森综合评分和生命质量评分,效果优于单纯盐酸苯海索治疗。

Objective: To observe effects of Pramipexole combined with Benzhexol hydrochloride in treatment of patients with Parkinson’s disease. Methods: A prospective study was conducted on 94 patients with Parkinson’s disease admitted to the hospital from August 2019 to August 2021. They were divided into control group and observation group according to the random number table method, 47 cases in each. The control group was treated with Benzhexol hydrochloride, while the observation group was treated with Pramipexole on the basis of that of the control group. The clinical efficacy, the unified Parkinson’s disease rating scale(UPDRS) score, the cognitive function [mini-mental state examination scale(MMSE)]score, the quality of life [39-item Parkinson’s disease quality of life questionnaire(PDQ-39)] score, the serological indicator levels [cystatin C(CysC),brain-derived neurotrophic factor(BDNF), interleukin-1β(IL-1β)], and the incidence of adverse reactions during treatment were compared between the two groups. Results: The total effective rate of treatment in the observation group was 93.62%(44/47), which was higher than 78.72%(37/47)in the control group, and the difference was statistically significant(P<0.05). After the treatment, the UPDRS scores of parts I, II and III in the two groups were lower than those before the treatment, those in the observation group were lower than those in the control group, and the differences were statistically significant(P<0.05). After the treatment, the MMSE score of the observation group was higher than that of the control group, the PDQ-39score was lower than that of the control group, and the differences were statistically significant(P<0.05). After the treatment, the levels of CysC and IL-1β in the two groups were lower than those before the treatment, and those of the observation group were lower than those of the control group;the levels of BDNF in the two groups were higher than those before the treatment, and that of the observation group was higher than that of the control group;and the differences were statistically significant(P<0.05). However, there was no significant difference in the incidence of adverse reactions between the two groups(P>0.05). Conclusions: Pramipexole combined with Benzhexol hydrochloride in the treatment of Parkinson’s disease can reduce and improve the total effective rate of treatment and the cognitive function score, improve the levels of serological indicators, and reduce the UPDRS score and the quality of life score. Moreover, it is superior to single Benzhexol hydrochloride treatment.